{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:31:52Z","timestamp":1790875912370,"version":"4.1.0"},"reference-count":73,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T00:00:00Z","timestamp":1680220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["No. 2017YFE0103400 \u7f16\u53f72017\u7ca4\u94c10103400"],"award-info":[{"award-number":["No. 2017YFE0103400 \u7f16\u53f72017\u7ca4\u94c10103400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Scleritis is a serious inflammatory eye disease that can lead to blindness. The etiology and pathogenesis of scleritis remain unclear, and increasing evidence indicates that some specific genes and proteins are involved. This study aimed to identify pivotal genes and drug targets for scleritis, thus providing new directions for the treatment of this disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We screened candidate genes and proteins associated with scleritis by text-mining the PubMed database using Python, and assessed their functions by using the DAVID database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were used to identify the functional enrichment of these genes and proteins. Then, the hub genes were identified with CytoHubba and assessed by protein-protein interaction (PPI) network analysis. And the serum from patients with active scleritis and healthy subjects were used for the validation of hub genes. Finally, the DGIdb database was used to predict targeted drugs for the hub genes for treating scleritis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 56 genes and proteins were found to be linked to scleritis, and 65 significantly altered pathways were identified in the KEGG analysis (FDR &amp;lt; 0.05). Most of the top five pathways involved the categories \u201cRheumatoid arthritis,\u201d \u201cInflammatory bowel disease\u201d, \u201cType I diabetes mellitus,\u201d and \u201cGraft-versus-host disease\u201d. TNF and IL6 were considered to be the top 2 hub genes through CytoHubba. Based on our serum samples, hub genes are expressed at high levels in active scleritis. Five scleritis-targeting drugs were found among 88 identified drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study provides key genes and drug targets related to scleritis through bioinformatics analysis. TNF and IL6 are considered key mediators and possible drug targets of scleritis. Five drug candidates may play an important role in the diagnosis and treatment of scleritis in the future, which is worthy of the further experimental and clinical study.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1098140","type":"journal-article","created":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T05:32:40Z","timestamp":1680240760000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Identifying TNF and IL6 as potential hub genes and targeted drugs associated with scleritis: A bio-informative report"],"prefix":"10.3389","volume":"14","author":[{"given":"Feiyue","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianlu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2005.04.001","article-title":"Scleritis","volume":"50","author":"Okhravi","year":"2005","journal-title":"Survey Ophthalmol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2014.110","article-title":"The impact of new methods of investigation and treatment on the understanding of the pathology of scleral inflammation","volume":"28","author":"Watson","year":"2014","journal-title":"Eye (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1097\/apo.0000000000000383","article-title":"Necrotizing syphilitic scleritis: The resurgence of syphilis in new Zealand","volume":"10","author":"Samalia","year":"2021","journal-title":"Asia-Pac J Ophthalmol (Philadelphia Pa.)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2017.1351572","article-title":"Posterior scleritis with choroidal effusion secondary to herpes zoster ophthalmicus","volume":"26","author":"Tsui","year":"2018","journal-title":"Ocular Immunol Inflammation"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.185","article-title":"Ocular inflammatory diseases associated with rheumatoid arthritis","volume":"10","author":"Artifoni","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preteyeres.2013.02.004","article-title":"Scleritis: Immunopathogenesis and molecular basis for therapy","volume":"35","author":"Wakefield","year":"2013","journal-title":"Prog Retinal Eye Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27492011000600004","article-title":"Comparative study of ophthalmological and serological manifestations and the therapeutic response of patients with isolated scleritis and scleritis associated with systemic diseases","volume":"74","author":"Sousa","year":"2011","journal-title":"Arquivos Brasileiros Oftalmol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/eye.2009.144","article-title":"Infectious scleritis and surgical induced necrotizing scleritis","volume":"24","author":"Lin","year":"2010","journal-title":"Eye (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.176038","article-title":"A case of giant nodular posterior scleritis mimicking choroidal malignancy","volume":"63","author":"Liu","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2016.06.002","article-title":"Treatment and management of scleral disorders","volume":"61","author":"Daniel Diaz","year":"2016","journal-title":"Survey Ophthalmol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-308561","article-title":"Morphological features in anterior scleral inflammation using swept-source optical coherence tomography with multiple b-scan averaging","volume":"101","author":"Kuroda","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2012-302130","article-title":"Ten-year experience of pulsed intravenous cyclophosphamide and methylprednisolone protocol (PICM protocol) in severe ocular inflammatory disease","volume":"97","author":"Khan","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2011-130282","article-title":"Scleritis: Presentations, disease associations and management","volume":"88","author":"Sims","year":"2012","journal-title":"Postgraduate Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2020.100866","article-title":"Activation of the interleukin-23\/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis","volume":"80","author":"Zhong","year":"2021","journal-title":"Prog Retinal Eye Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/brv.12457","article-title":"Comprehensive review of hepatitis b virus-associated hepatocellular carcinoma research through text mining and big data analytics","volume":"94","author":"Lee","year":"2019","journal-title":"Biol Rev Cambridge Philos Soc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.587443","article-title":"Integrated analysis of key pathways and drug targets associated with vogt-Koyanagi-Harada disease","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbx103","article-title":"MetSigDis: A manually curated resource for the metabolic signatures of diseases","volume":"20","author":"Cheng","year":"2019","journal-title":"Briefings Bioinf"},{"key":"B18","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","article-title":"DAVID: Database for annotation, visualization, and integrated discovery","volume":"4","author":"Dennis","year":"2003","journal-title":"Genome Biol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12911-018-0694-7","article-title":"Automatic gene annotation using GO terms from cellular component domain","volume":"18","author":"Ding","year":"2018","journal-title":"BMC Med Inf Decision Making"},{"key":"B20","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","article-title":"KEGG: New perspectives on genomes, pathways, diseases and drugs","volume":"45","author":"Kanehisa","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"D605","DOI":"10.1093\/nar\/gkaa1074","article-title":"The STRING database in 2021: Customizable protein-protein networks, and functional characterization of user-uploaded gene\/measurement sets","volume":"49","author":"Szklarczyk","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00695","article-title":"Identification of potential crucial genes and key pathways in breast cancer using bioinformatic analysis","volume":"10","author":"Deng","year":"2019","journal-title":"Front Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.726747","article-title":"Identifying immune cell infiltration and effective diagnostic biomarkers in rheumatoid arthritis by bioinformatics analysis","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.60.3.163","article-title":"Scleritis and episcleritis","volume":"60","author":"Watson","year":"1976","journal-title":"Br J Ophthalmol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"D1144","DOI":"10.1093\/nar\/gkaa1084","article-title":"Integration of the drug-gene interaction database (DGIdb 4.0) with open crowdsource efforts","volume":"49","author":"Freshour","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8294560","DOI":"10.1155\/2020\/8294560","article-title":"New potential weapons for refractory scleritis in the era of targeted therapy","volume":"2020","author":"Fabiani","year":"2020","journal-title":"Mediators Inflamm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e05932","DOI":"10.1002\/ccr3.5932","article-title":"Dilemma of tocilizumab therapy for a patient with critical COVID-19 disease and neutropenia: Case report and review of the literature","volume":"10","author":"Al Bishawi","year":"2022","journal-title":"Clin Case Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/09273940802596500","article-title":"Recalcitrant granulomatous sclerouveitis in a patient with granulomatous ANCA-associated vasculitis","volume":"17","author":"Levy-Clarke","year":"2009","journal-title":"Ocular Immunol Inflammation"},{"key":"B29","article-title":"[New methods of therapy for ocular inflammatory autoimmune diseases]","volume":"105","author":"Kubicka-Trzaska","year":"2003","journal-title":"Klinika Oczna"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/08164622.2021.1971047","article-title":"Keeping an \u2018eye\u2019 on ocular GVHD","volume":"105","author":"Kezic","year":"2022","journal-title":"Clin Exp Optomet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1939390","article-title":"A review of ocular graft-versus-Host disease: Pathophysiology, clinical presentation and management","volume":"29","author":"Carreno-Galeano","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.04.011","article-title":"Vision-related quality of life in patients with ocular graft-versus-Host disease","volume":"122","author":"Saboo","year":"2015","journal-title":"Ophthalmology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.925929","article-title":"Comparison of intestinal microbes in noninfectious anterior scleritis patients with and without rheumatoid arthritis","volume":"13","author":"Li","year":"2022","journal-title":"Front Microbiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e052833","DOI":"10.1136\/bmjopen-2021-052833","article-title":"Risk of a subsequent diagnosis of inflammatory bowel disease in subjects with ophthalmic disorders associated with inflammatory bowel disease: a retrospective cohort analysis of UK primary care data","volume":"12","author":"King","year":"2022","journal-title":"BMJ Open"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3928\/01913913-20080101-20","article-title":"Bilateral necrotizing scleritis following strabismus surgery for thyroid ophthalmopathy","volume":"45","author":"Streho","year":"2008","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-017-0479-9","article-title":"Systemic lupus erythematosus and ocular involvement: An overview","volume":"18","author":"Dammacco","year":"2018","journal-title":"Clin Exp Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0886-3350(98)80302-7","article-title":"Postoperative rhizopus scleritis in a diabetic man","volume":"24","author":"Locher","year":"1998","journal-title":"J Cataract Refractive Surg"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4103\/jovr.jovr_122_16","article-title":"Combined tenonplasty and scleral graft for refractory pseudomonas scleritis following pterygium removal with mitomycin c application","volume":"13","author":"Siatiri","year":"2018","journal-title":"J Ophthalmic Vision Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2018.03.008","article-title":"Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden","volume":"32","author":"Ansari","year":"2018","journal-title":"J Diabetes its Complications"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102118","article-title":"Rheumatoid arthritis associated episcleritis and scleritis: An update on treatment perspectives","volume":"10","author":"Promelle","year":"2021","journal-title":"J Clin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-006-9005-3","article-title":"TNF-alpha in promotion and progression of cancer","volume":"25","author":"Balkwill","year":"2006","journal-title":"Cancer Metastasis Rev"},{"key":"B42","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcq152","article-title":"TNF-\u03b1 antagonists beyond approved indications: Stories of success and prospects for the future","volume":"103","author":"Karampetsou","year":"2010","journal-title":"QJM: Monthly J Assoc Phys"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2016.1241282","article-title":"Clinical features and complications of scleritis in Chinese patients","volume":"26","author":"Yang","year":"2018","journal-title":"Ocular Immunol Inflammation"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.06.006","article-title":"Evaluation of patients with scleritis for systemic disease","volume":"111","author":"Akpek","year":"2004","journal-title":"Ophthalmology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3899\/jrheum.190768","article-title":"Ocular manifestations in rheumatoid arthritis, connective tissue disease, and vasculitis: A systematic review and metaanalysis","volume":"48","author":"Turk","year":"2021","journal-title":"J Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000090010","article-title":"Expression of tumor necrosis factor alpha and matrix metalloproteinase-9 in surgically induced necrotizing scleritis","volume":"38","author":"Seo","year":"2006","journal-title":"Ophthalmic Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1521-4141(199806)28:06<1773::aid-immu1773>3.0.co;2-b","article-title":"Expression of matrix metalloproteinases by human plasma cells and b lymphocytes","volume":"28","author":"Di Girolamo","year":"1998","journal-title":"Eur J Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7152","article-title":"Two interferon mRNAs in human fibroblasts: in vitro translation and escherichia coli cloning studies","volume":"77","author":"Weissenbach","year":"1980","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-2291","article-title":"Interleukin-6 as a therapeutic target","volume":"21","author":"Rossi","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-021-01985-y","article-title":"Scleraxis expressing scleral cells respond to inflammatory stimulation","volume":"156","author":"Atta","year":"2021","journal-title":"Histochem Cell Biol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.22088\/cjim.13.3.642","article-title":"Giant cell arteritis and scleritis: A rare association","volume":"13","author":"Zulfiqar","year":"2022","journal-title":"Caspian J Internal Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2008.150961","article-title":"Infliximab for the treatment of refractory scleritis","volume":"94","author":"Doctor","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/8v3f7i","article-title":"Adalimumab for refractory idiopathic scleritis in children","volume":"40","author":"Gaggiano","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00941","article-title":"Effectiveness and safety of anti-tumor necrosis factor-alpha agents treatment in behcets\u2019 disease-associated uveitis: A systematic review and meta-analysis","volume":"11","author":"Hu","year":"2020","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0627-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of infliximab in the treatment of inflammatory bowel disease","volume":"57","author":"Hemperly","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1080\/09273940600659393","article-title":"Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature","volume":"14","author":"Taban","year":"2006","journal-title":"Ocular Immunol Inflammation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110865","article-title":"Scleritis: A paradoxical effect of etanercept? etanercept-associated inflammatory eye disease","volume":"39","author":"Gaujoux-Viala","year":"2012","journal-title":"J Rheumatol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-015-0124-0","article-title":"Biologic therapy for refractory scleritis: A new treatment perspective","volume":"35","author":"de Fidelix","year":"2015","journal-title":"Int Ophthalmol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13641","article-title":"Pharmacokinetics and c-reactive protein modelling of anti-interleukin-6 antibody (PF-04236921) in healthy volunteers and patients with autoimmune disease","volume":"84","author":"Li","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209668","article-title":"Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial","volume":"76","author":"Wallace","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevEukaryotGeneExpr.2017019712","article-title":"Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus","volume":"27","author":"Rehman","year":"2017","journal-title":"Crit Rev Eukaryotic Gene Expression"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22094672","article-title":"Insulin signaling as a therapeutic target in glaucomatous neurodegeneration","volume":"22","author":"Al Hussein Al Awamlh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00449.2010","article-title":"Neurodegeneration in an animal model of parkinson\u2019s disease is exacerbated by a high-fat diet","volume":"299","author":"Morris","year":"2010","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040503","article-title":"Diabetes mellitus induces alzheimer\u2019s disease pathology: Histopathological evidence from animal models","volume":"17","author":"Kimura","year":"2016","journal-title":"Int J Mol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2016.12.013","article-title":"Insulin attenuates TNF\u03b1-induced hemopexin mRNA: An anti-inflammatory action of insulin in rat H4IIE hepatoma cells","volume":"9","author":"Franklin","year":"2017","journal-title":"Biochem Biophys Rep"},{"key":"B67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2147\/hmer.s7083","article-title":"Anti-inflammatory action of insulin via induction of Gadd45-\u03b2 transcription by the mTOR signaling pathway","volume":"2001","author":"Bortoff","year":"2010","journal-title":"Hepatic Med: Evid Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1677\/joe.1.05977","article-title":"Prolonged insulin treatment inhibits GH signaling via STAT3 and STAT1","volume":"184","author":"Xu","year":"2005","journal-title":"J Endocrinol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1186\/cc1501","article-title":"Insulin and the critically ill","volume":"6","author":"Das","year":"2002","journal-title":"Crit Care (London England)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051497","article-title":"Possible beneficial action(s) of glucose-insulin-potassium regimen in acute myocardial infarction and inflammatory conditions: A hypothesis","volume":"43","author":"Das","year":"2000","journal-title":"Diabetologia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/s0899-9007(01)00518-4","article-title":"Is insulin an antiinflammatory molecule","volume":"17","author":"Das","year":"2001","journal-title":"Nutr (Burbank Los Angeles County Calif.)"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1054\/mehy.2001.1334","article-title":"Can glucose-insulin-potassium regimen suppress inflammatory bowel disease","volume":"57","author":"Das","year":"2001","journal-title":"Med Hypotheses"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2020.01.23","article-title":"Molecular pathobiology of scleritis and its therapeutic implications","volume":"13","author":"Das","year":"2020","journal-title":"Int J Ophthalmol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098140\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T05:32:49Z","timestamp":1680240769000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1098140\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":73,"alternative-id":["10.3389\/fimmu.2023.1098140"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1098140","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"article-number":"1098140"}}